Axovant Sciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Axovant Sciences sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Axovant Sciences: 8 sponsored US clinical trials, none currently recruiting.

Axovant Sciences sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Visual Hallucinations, with 1 trials.

Upper-quartile sponsor footprint

Axovant Sciences sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

TERMINATED Phase 2

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

NCT02871427
COMPLETED Phase 2

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

NCT02910102
TERMINATED Phase 2

Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

NCT02928445
TERMINATED Phase 3

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

NCT02586909
COMPLETED Phase 2

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

NCT02708186
COMPLETED Phase 2

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

NCT02669433
COMPLETED Phase 2

Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia

NCT02640729
COMPLETED Phase 3

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

NCT02585934

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 2

Therapeutic Areas

Visual Hallucinations 1
Lewy Body Dementia 1

How the Axovant Sciences early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Visual Hallucinations (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Axovant Sciences: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Axovant Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Axovant SciencesAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Axovant Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Axovant Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Axovant Sciences page

8 registered trials is a research-attention snapshot, not an endorsement of Axovant Sciences or any single study.

  • None of Axovant Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Visual Hallucinations is the condition Axovant Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Visual Hallucinations trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Axovant Sciences pipeline card: 8 registered trials from official public datasets.Report a data error.